| Evidence establishing a link between prenatal and early-life stress and asthma development |
15 |
| Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence |
13 |
| Recombinant allergens for immunotherapy: state of the art |
12 |
| Is the evidence of local allergic rhinitis growing? |
11 |
| Asthma: personalized and precision medicine |
11 |
| Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018 |
10 |
| Strategies to reduce corticosteroid-related adverse events in asthma |
8 |
| Development of allergic sensitization and its relevance to paediatric asthma |
8 |
| Role of epigenetics in the development of childhood asthma |
8 |
| Hypersensitivity reactions to beta-lactams in children |
8 |
| Making a diagnosis in severe cutaneous drug hypersensitivity reactions |
8 |
| The role of component-resolved diagnosis in Hymenoptera venom allergy |
8 |
| Manufacturing and quality assessment of allergenic extracts for immunotherapy: state of the art |
7 |
| Duration of allergen immunotherapy for inhalant allergy |
7 |
| New findings, pathophysiology, and antigen analysis in pollen-food allergy syndrome |
7 |
| Role of IL-35 in sublingual allergen immunotherapy |
7 |
| Bronchiectasis and asthma: a dangerous liaison? |
7 |
| Biomarkers and asthma management: analysis and potential applications |
7 |
| Mechanisms leading to T-cell activation in drug hypersensitivity |
7 |
| Association between allergic and nonallergic rhinitis and obstructive sleep apnea |
7 |
| Eosinophilic esophagitis during sublingual and oral allergen immunotherapy |
7 |
| Vitamin D and childhood asthma: causation and contribution to disease activity |
6 |
| Microbiome and disease in the upper airway |
6 |
| Very early onset IBD: novel genetic aetiologies |
6 |
| Management of adverse reactions to first-line tuberculosis antibiotics |
6 |
| Microbiome and skin biology |
6 |
| Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends |
6 |
| Gender aspects in food allergy |
6 |
| Clozapine-associated secondary antibody deficiency |
5 |
| Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells |
5 |
| Innate lymphoid cells in asthma: pathophysiological insights from murine models to human asthma phenotypes |
5 |
| How to diagnose food allergy |
5 |
| Ocular allergy as a risk factor for dry eye in adults and children |
5 |
| New biologics in the treatment of urticaria |
5 |
| Precision medicine in food allergy |
5 |
| The impact of exercise on asthma |
5 |
| Assessing the impact of air pollution on childhood asthma morbidity: how, when, and what to do |
4 |
| Asthma exacerbation prediction: recent insights |
4 |
| NSAIDs hypersensitivity: questions not resolved |
4 |
| Prevalence and clinical characteristics of local allergic rhinitis to house dust mites |
4 |
| Adults and children with anaphylaxis in the emergency room: why it is not recognized? |
4 |
| Collection of nasal secretions and tears and their use in allergology |
4 |
| Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next? |
4 |
| Biologics and anaphylaxis |
4 |
| Topical tacrolimus for allergic eye diseases |
4 |
| B-cell responses in allergen immunotherapy |
4 |
| Tryptase values in anaphylaxis and insect allergy |
3 |
| Role of the ocular surface microbiome in allergic disease |
3 |
| Ocular allergy: update on clinical trials |
3 |
| Current market trends in anterior ocular inflammatory disease landscape |
3 |
